Akoya Biosciences Inc (AKYA)
4.27
-0.20
(-4.47%)
USD |
NASDAQ |
May 10, 16:00
4.27
0.00 (0.00%)
After-Hours: 18:45
Akoya Biosciences Research and Development Expense (Quarterly): 4.67M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.67M |
| September 30, 2023 | 5.173M |
| June 30, 2023 | 6.273M |
| March 31, 2023 | 5.773M |
| December 31, 2022 | 6.433M |
| September 30, 2022 | 5.466M |
| June 30, 2022 | 5.598M |
| March 31, 2022 | 5.714M |
| Date | Value |
|---|---|
| December 31, 2021 | 5.563M |
| September 30, 2021 | 3.999M |
| June 30, 2021 | 2.947M |
| March 31, 2021 | 3.192M |
| December 31, 2020 | 2.532M |
| September 30, 2020 | 2.279M |
| June 30, 2020 | 2.42M |
| March 31, 2020 | 2.372M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.279M
Minimum
Sep 2020
6.433M
Maximum
Dec 2022
4.400M
Average
4.922M
Median
Research and Development Expense (Quarterly) Benchmarks
| Bruker Corp | 81.70M |
| Azenta Inc | 8.493M |
| Harvard Bioscience Inc | 3.15M |
| Bionano Genomics Inc | 11.70M |
| Singular Genomics Systems Inc | 11.69M |